Reimagining Medicine Q2 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
LeqvioⓇ adoption expanding as we progress the launch
LeqvioⓇ launch progressing steadily
Global sales evolution
USD m
Ex-US
US
22
22
42
34
64
19
Building foundation for acceleration
US adoption
2,600 facilities have ordered Leqvio (+18% vs. Q1)
78
Buy & bill 54% of Leqvio demand (+16% vs. Q1)
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Early adopters driving Leqvio depth
Clinical profile
Consistent safety vs. Ph3 studies beyond 5yr follow-up in
pooled analysis across 7 clinical trials1
Label expansion in US: indication updated to
☐
Primary hyperlipidemia incl. HeFH
Less restrictive language for use for statin therapy
Removal of several adverse reactions from safety section
GROWTH
HCP healthcare professional. LTD - Launch To Date. *Leqvio® is administered initially, again at 3 months, and then once every 6 months. Novartis has obtained global rights to develop, manufacture and commercialize LeqvioⓇ under a
license agreement with Alnylam Pharmaceuticals 1. Wright RS. Oral presentation at: American College of Cardiology Annual Conference; March 2023.
13 Investor Relations | Q2 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation